Fast Tracked Reviews and Complaints Another feature tied to Fast Tracked status is enhanced written communication from the agency: when a product is Fast Tracked, sponsors typically receive more detailed written responses on questions about endpoints, statistical analysis plans, and the acceptability of surrogate markers, and this creates a documented trail that teams can use to align internal decisions with regulator expectations. Fast Tracked status also increases the likelihood of Priority Review designation if the totality of evidence warrants it, and while Fast Tracked does not guarantee Priority Review, products that are Fast Tracked often are better positioned because the earlier dialogues help crystallize the clinical value proposition that underlies Priority Review. It is also a feature of Fast Tracked that the designation can be requested at multiple time points — even at or shortly after IND filing — making Fast Tracked an accessible option for sponsors who have mechanistic rationale or nonclinical evidence suggesting potential benefits in serious conditions. Fast Tracked does not have a monetary price tag: there is no fee to obtain Fast Tracked status itself, though sponsors still pay standard user fees for NDAs or BLAs, and when a product is Fast Tracked there is an implicit operational commitment to maintain the criteria for the designation since the FDA can remove the Fast Tracked label if later evidence fails to support the original rationale.
Fast Tracked Reviews and Complaints Fast Tracked also involves ancillary features and procedural behaviors that influence how development teams prepare programs and allocate resources, and understanding those additional features gives a complete picture of what Fast Tracked really means for a project. Another practical feature tied to Fast Tracked is its role as an entry point to other expedited pathways: Fast Tracked designation makes it easier to have candid discussions about whether Accelerated Approval using surrogate endpoints is appropriate or whether the product might meet the evidentiary bar for Breakthrough Therapy designation later if emerging clinical data show substantial improvement, and that interplay is a strategic feature companies consider when they seek Fast Tracked. The Fast Tracked pathway also includes the feature that the FDA can withdraw the designation if ongoing evidence no longer supports the original basis for Fast Tracked; sponsors must therefore commit to monitoring their development data and communicating material changes, a governance feature that keeps the Fast Tracked process evidence-based. In non-regulatory contexts, Fast Tracked is sometimes confused with CRM software called Fast Track, but when focusing on drug development it is critical to keep the Fast Tracked regulatory meaning separate: the Fast Tracked program's specifications center on meeting criteria for serious conditions and unmet needs, and that lens informs how trials are structured, how endpoints are chosen, and how resources are marshalled. Order Now Buy Fast Tracked Today